Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ANG-Lifesciences"

4 News Found

ANG Lifesciences India updates on acquisition of unit from Ind-Swift
News | June 28, 2024

ANG Lifesciences India updates on acquisition of unit from Ind-Swift

This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres

ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr
News | June 08, 2022

ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr

The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.

ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
Biotech | August 18, 2021

ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr

The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization

ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore
News | October 26, 2021

ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore

ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging